ClinicalTrials.gg
CompletedNCT02539225Updated Mar 8, 2022Results posted

A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 2 interventional study of Ramucirumab and Placebo in Metastatic Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by Eli Lilly and Company. Completed at 34 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-03-08.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
191
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

The main purpose of this study is to evaluate the effectiveness of S-1 and oxaliplatin with or without ramucirumab as first line therapy in participants with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

02

Conditions studied

  • Metastatic Gastric Adenocarcinoma
  • Gastroesophageal Junction Adenocarcinoma
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a histopathologically or confirmed diagnosis of gastric or GEJ adenocarcinoma. Participants with esophageal cancer are not eligible.
  • Have not received any prior systemic therapy for gastric or GEJ adenocarcinoma (prior or neoadjuvant therapy is permitted). Participants whose disease has progressed after >24 weeks following the last dose of systemic treatment in the adjuvant/neoadjuvant setting are eligible.
  • Have measurable or nonmeasurable but evaluable disease determined using guidelines in , Version 1.1 (RECIST v.1.1).
  • Have a performance status of 0 or 1 on the (ECOG) scale at baseline.
  • Have adequate organ function.
  • Have an estimated of ≥12 weeks in the judgment of the investigator.
  • Eligible participants of (both sexes) must agree to use (hormonal or barrier methods) during the study period and at least 6 months after the last dose of study treatment or longer if required per local regulations.
  • Are willing to provide a blood sample for research purposes. Submission of a blood sample is mandatory for participation in this study unless restricted by local regulations or ethical review boards (ERBs); submission of a tumor tissue sample is optional.

Exclusion criteria

Exclusion Criteria:

  • Participants with human epidermal growth factor receptor 2 ()-positive status as determined per local standards. Participants with a negative test or having an indeterminate result due to any reason are eligible, provided these participants are not eligible for treatment directed against tumors which overexpress HER2.
  • Have radiation therapy within 14 days prior to randomization. Any lesion requiring palliative radiation or which has been previously irradiated cannot be considered for response assessment.
  • Have documented , , or uncontrolled spinal cord compression.
  • Have undergone major surgery within 28 days prior to randomization.
  • Are currently enrolled in, or discontinued study drug within the last 28 days from, a clinical trial involving an product or non-approved use of a drug or device (other than the study drug used in this study), or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. Participants participating in surveys or observational studies are eligible to participate in this study.
  • Are pregnant or breast feeding. Females of must have a negative serum or urine pregnancy test within 7 days prior to first dose of study treatment.
  • Have any prior .
  • Have any condition (eg, psychological, geographical, or medical) that does not permit compliance with the study and follow-up procedures or suggest that the participant is, in the investigator's opinion, not an appropriate candidate for the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
191 participants (actual)

Study arms

  • Experimental
    S-1/Oxaliplatin + Ramucirumab

    (Part A) Ramucirumab intravenously (IV) on day 1 and day 8 along with S-1 by mouth (PO) on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B. (Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.

    Drug: Ramucirumab · Drug: S-1 · Drug: Oxaliplatin · Drug: Paclitaxel

  • Active comparator
    S-1/Oxaliplatin + Placebo

    (Part A) Placebo IV on day 1 and day 8 along with S-1 PO on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B. (Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.

    Drug: Ramucirumab · Drug: Placebo · Drug: S-1 · Drug: Oxaliplatin · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from the date of randomization until the date of objectively determined progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause, whichever is first. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 millimeter (mm) or the appearance of ≥1 new lesions was progression. Participants who did not progress, were lost to follow-up were censored at the day of their last adequate tumor assessment.

    Time frame: Randomization to Radiographic Documentation of Progression or Death Due to Any Cause (Up to 25 Months)

Secondary outcomes

  1. Progression-free Survival to the Second Disease Progression (PFS 2)

    Progression-free survival 2 (PFS2) is defined as the time from the date of randomization to second disease progression (defined as the date of first tumor assessment observing PD defined by RECIST v.1.1, after the start of second-line therapy using the last tumor assessment before starting the second-line therapy (RAM+PTX) as the baseline assessment), or death of any cause, whichever occurs first. If the second-line therapy was not started, the OS will be substituted for PFS2. If a post-discontinuation therapy was started before observing PD after the start of second-line therapy. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. PFS2 will be censored at the date of the last adequate tumor assessment on or before staring the post-discontinuation therapy.

    Time frame: Randomization to Second Radiographic Documentation of Progression or Death Due to Any Cause (Up to 31 Months)

  2. Overall Survival (OS)

    Overall survival is defined as time from the date of randomization to the date of death from any cause. If the patient was alive at the cut-off for analysis (or lost to follow-up), OS data were censored for analysis on the last date the patient was known to be alive.

    Time frame: Randomization to Death Due to Any Cause (Up to 31 Months)

  3. Percentage of Participants With Objective Response Rate (ORR)

    The ORR is the number of all participants with Partial Response (PR) or Complete Response (CR) according to RECIST v1.1 from the start of the treatment until disease progression/recurrence. CR is defined as the disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \<10 mm. PR is defined as ≥30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 mm or the appearance of ≥1 new lesions was progression.

    Time frame: Randomization to Disease Progression (Up to 25 Months)

  4. Disease Control Rate (DCR)

    Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 mm or the appearance of ≥1 new lesions was progression.

    Time frame: Randomization to Disease Progression (Up to 25 Months)

  5. Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part A

    Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part A.

    Time frame: Cycle 1 Day 1 & 8 Predose, Cycle 2 Day 1 Predose, Cycle 3 Day 1 Predose, Cycle 5 Day 1 Predose, Cycle 9 Day 1 Predose

  6. Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part B

    Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part B.

    Time frame: Cycle 1 Day 1 predose, Cycle 2 Day 1 predose

  7. Number of Participants With Anti-Ramucirumab Antibodies

    Participant is considered as treatment emergent anti-drug antibody (TE ADA) positive if the participant has at least one post baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post baseline result of ADA Present with titer \>= 20.

    Time frame: Baseline through 25 months

07

Results

Posted Feb 15, 2019

Participant flow

Completers are defined as participants who died or those who were alive and off treatment at study completion.

Part A
Participant flow — Part A
MilestoneRamucirumab + S-1 + OxaliplatinPlacebo + S-1 + Oxaliplatin
Started9794
Received any quantity of study drug9693
Completed7778
Not completed2016
Withdrew: Adverse event134
Withdrew: Withdrawal by subject24
Withdrew: Physician decision47
Withdrew: Did not receive study drug11
Pre Treatment for Part B
Participant flow — Pre Treatment for Part B
MilestoneRamucirumab + S-1 + OxaliplatinPlacebo + S-1 + Oxaliplatin
Started6366
Completed5864
Not completed52
Withdrew: Progressive disease11
Withdrew: Adverse event11
Withdrew: Withdrawal by subject10
Withdrew: Physician decision20
Part B
Participant flow — Part B
MilestoneRamucirumab + S-1 + OxaliplatinPlacebo + S-1 + Oxaliplatin
Started5864
Completed5448
Not completed416
Withdrew: Adverse event44
Withdrew: Withdrawal by subject03
Withdrew: Physician decision09

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS is defined as the time from the date of randomization until the date of objectively determined progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause, whichever is first. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 millimeter (mm) or the appearance of ≥1 new lesions was progression. Participants who did not progress, were lost to follow-up were censored at the day of their last adequate tumor assessment.

Time frame:
Randomization to Radiographic Documentation of Progression or Death Due to Any Cause (Up to 25 Months)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsRamucirumab + S-1 + OxaliplatinPlacebo + S-1 + Oxaliplatin
Progression Free Survival (PFS)6.34 (5.65 to 6.93)6.74 (5.75 to 7.13)
Statistical analysis
  • Ramucirumab + S-1 + Oxaliplatin vs Placebo + S-1 + Oxaliplatin · Stratified Log Rank · p = 0.698
SecondaryProgression-free Survival to the Second Disease Progression (PFS 2)

Progression-free survival 2 (PFS2) is defined as the time from the date of randomization to second disease progression (defined as the date of first tumor assessment observing PD defined by RECIST v.1.1, after the start of second-line therapy using the last tumor assessment before starting the second-line therapy (RAM+PTX) as the baseline assessment), or death of any cause, whichever occurs first. If the second-line therapy was not started, the OS will be substituted for PFS2. If a post-discontinuation therapy was started before observing PD after the start of second-line therapy. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. PFS2 will be censored at the date of the last adequate tumor assessment on or before staring the post-discontinuation therapy.

Time frame:
Randomization to Second Radiographic Documentation of Progression or Death Due to Any Cause (Up to 31 Months)
Reported as:
Median · Months
Progression-free Survival to the Second Disease Progression (PFS 2)
MonthsRamucirumab + S-1 + OxaliplatinPlacebo + S-1 + Oxaliplatin
Progression-free Survival to the Second Disease Progression (PFS 2)10.94 (9.63 to 12.52)11.99 (9.82 to 13.83)
Statistical analysis
  • Ramucirumab + S-1 + Oxaliplatin vs Placebo + S-1 + Oxaliplatin · Log Rank Stratified · p = 0.549
SecondaryOverall Survival (OS)

Overall survival is defined as time from the date of randomization to the date of death from any cause. If the patient was alive at the cut-off for analysis (or lost to follow-up), OS data were censored for analysis on the last date the patient was known to be alive.

Time frame:
Randomization to Death Due to Any Cause (Up to 31 Months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsRamucirumab + S-1 + OxaliplatinPlacebo + S-1 + Oxaliplatin
Overall Survival (OS)14.65 (12.39 to 15.67)14.26 (13.83 to 17.31)
Statistical analysis
  • Ramucirumab + S-1 + Oxaliplatin vs Placebo + S-1 + Oxaliplatin · Log Rank Stratified · p = 0.548
SecondaryPercentage of Participants With Objective Response Rate (ORR)

The ORR is the number of all participants with Partial Response (PR) or Complete Response (CR) according to RECIST v1.1 from the start of the treatment until disease progression/recurrence. CR is defined as the disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to \<10 mm. PR is defined as ≥30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 mm or the appearance of ≥1 new lesions was progression.

Time frame:
Randomization to Disease Progression (Up to 25 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response Rate (ORR)
percentage of participantsRamucirumab + S-1 + OxaliplatinPlacebo + S-1 + Oxaliplatin
Percentage of Participants With Objective Response Rate (ORR)58.2 (49.7 to 66.7)50.0 (41.3 to 58.7)
Statistical analysis
  • Ramucirumab + S-1 + Oxaliplatin vs Placebo + S-1 + Oxaliplatin · Cochran-Mantel-Haenszel · p = 0.402 · Odds ratio (or): 1.374 · 80% CI 0.844 to 2.236
SecondaryDisease Control Rate (DCR)

Disease Control Rate (DCR) was the percentage of participants with a best overall response of CR, PR, or Stable Disease (SD) as per Response using RECIST v1.1 criteria. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. Disease progression is defined as ≥20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of ≥5 mm or the appearance of ≥1 new lesions was progression.

Time frame:
Randomization to Disease Progression (Up to 25 Months)
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsRamucirumab + S-1 + OxaliplatinPlacebo + S-1 + Oxaliplatin
Disease Control Rate (DCR)90.9 (85.9 to 95.9)87 (81.2 to 92.9)
Statistical analysis
  • Ramucirumab + S-1 + Oxaliplatin vs Placebo + S-1 + Oxaliplatin · Cochran-Mantel-Haenszel · p = 0.501 · Odds ratio (or): 1.527 · 80% CI 0.680 to 3.433
SecondaryPharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part A

Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part A.

Time frame:
Cycle 1 Day 1 & 8 Predose, Cycle 2 Day 1 Predose, Cycle 3 Day 1 Predose, Cycle 5 Day 1 Predose, Cycle 9 Day 1 Predose
Reported as:
Geometric mean · Microgram per milliliter (ug/mL)
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part A
Microgram per milliliter (ug/mL)Ramucirumab + S-1 + Oxaliplatin - Part A
Cycle 1 Day 1NA ± NA
Cycle 1 Day 842.6 ± 32
Cycle 2 Day 141.4 ± 40
Cycle 3 Day 159.4 ± 51
Cycle 5 Day 183.6 ± 37
Cycle 9 Day 194.6 ± 38
SecondaryPharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part B

Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part B.

Time frame:
Cycle 1 Day 1 predose, Cycle 2 Day 1 predose
Reported as:
Geometric mean · Microgram per milliliter (ug/mL)
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab in Part B
Microgram per milliliter (ug/mL)Ramucirumab + S-1 + Oxaliplatin Part BPlacebo + S-1 + Oxaliplatin - Part B
Cycle 1 Day 152.0 ± 65NA ± NA
Cycle 2 Day 158.1 ± 4041.0 ± 45
SecondaryNumber of Participants With Anti-Ramucirumab Antibodies

Participant is considered as treatment emergent anti-drug antibody (TE ADA) positive if the participant has at least one post baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post baseline result of ADA Present with titer \>= 20.

Time frame:
Baseline through 25 months
Reported as:
Count of participants · Participants
Number of Participants With Anti-Ramucirumab Antibodies
ParticipantsRamucirumab + S-1 + OxaliplatinPlacebo + S-1 + Oxaliplatin
Number of Participants With Anti-Ramucirumab Antibodies13

Adverse events

Collected over Up to 31 Months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab + S-1 + Oxaliplatin - Part A2/96 (2.1%)29/96 (30.2%)95/96 (99%)
Placebo + S-1 + Oxaliplatin - Part A1/93 (1.1%)24/93 (25.8%)93/93 (100%)
Ramucirumab + S-1 + Oxaliplatin Part B1/58 (1.7%)16/58 (27.6%)58/58 (100%)
Placebo + S-1 + Oxaliplatin - Part B0/64 (0%)14/64 (21.9%)64/64 (100%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventRamucirumab + S-1 + Oxaliplatin - Part APlacebo + S-1 + Oxaliplatin - Part ARamucirumab + S-1 + Oxaliplatin Part BPlacebo + S-1 + Oxaliplatin - Part B
Febrile neutropeniaBlood and lymphatic system disorders1/960/933/584/64
Gastric perforationGastrointestinal disorders1/961/933/580/64
PyelonephritisInfections and infestations0/960/932/580/64
Abdominal painGastrointestinal disorders1/963/931/580/64
Upper gastrointestinal haemorrhageGastrointestinal disorders3/960/930/581/64
VomitingGastrointestinal disorders3/962/930/581/64
AnaemiaBlood and lymphatic system disorders0/962/930/580/64
EnterocolitisGastrointestinal disorders0/962/930/580/64
Gastric stenosisGastrointestinal disorders0/962/930/580/64
DiarrhoeaGastrointestinal disorders2/960/930/580/64
Most frequent other events
Showing 10 of 420
Most frequent other events
EventRamucirumab + S-1 + Oxaliplatin - Part APlacebo + S-1 + Oxaliplatin - Part ARamucirumab + S-1 + Oxaliplatin Part BPlacebo + S-1 + Oxaliplatin - Part B
Peripheral sensory neuropathyNervous system disorders56/9670/938/5814/64
Decreased appetiteMetabolism and nutrition disorders53/9657/939/5812/64
Neutrophil count decreasedInvestigations48/9632/9333/5836/64
NauseaGastrointestinal disorders54/9637/935/584/64
DiarrhoeaGastrointestinal disorders49/9628/9310/588/64
AlopeciaSkin and subcutaneous tissue disorders10/962/9326/5830/64
White blood cell count decreasedInvestigations24/9618/9319/5824/64
ConstipationGastrointestinal disorders33/9630/933/586/64
Platelet count decreasedInvestigations33/9628/934/584/64
VomitingGastrointestinal disorders28/9621/935/587/64

Baseline characteristics

All randomized participants who received any quantity of study drug.

Age, Continuous
Age, Continuous(Years)Ramucirumab + S-1 + OxaliplatinPlacebo + S-1 + OxaliplatinTotal
Mean59.2 ± 12.3561.3 ± 11.5360.2 ± 11.97
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab + S-1 + OxaliplatinPlacebo + S-1 + OxaliplatinTotal
Female392968
Male5764121
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ramucirumab + S-1 + OxaliplatinPlacebo + S-1 + OxaliplatinTotal
Hispanic or Latino000
Not Hispanic or Latino000
Unknown or Not Reported9693189
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ramucirumab + S-1 + OxaliplatinPlacebo + S-1 + OxaliplatinTotal
American Indian or Alaska Native000
Asian9693189
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Ramucirumab + S-1 + OxaliplatinPlacebo + S-1 + OxaliplatinTotal
South Korea202040
Japan6564129
Taiwan11920
08

Study locations

34 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Akashi, 673-8558, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bunkyo-Ku, 113-8677, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 260-8717, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gifu, 501-1194, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kochi, 781-8555, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Koto-ku, 135-8550, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Koto-ku, 135-8577, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kumamoto, 860-8556, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagoya, 464-8681, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nagoya, 466-8560, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 534-0021, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 541-8567, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 558-8558, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sagamihara, 252-0375, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sakai, 593-8304, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sapporo, 060-8648, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shinjuku-Ku, 160-8582, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Suita-shi, 565-0871, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Takatsuki, 569-8686, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Toyonaka, 560-8565, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Utsunomiya, 320-0834, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yokohama, 224-8503, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yokohama, 241-8515, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 03080, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 03722, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 05505, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 06273, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 06351, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ulsan-si, 44033, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kuei Shan Hsiang, 33305, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taichung, 40447, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tainan, 70403, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 10048, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Taipei, 11217, Taiwan
09

References and documents

Publications

  • Yoshikawa T, Muro K, Shitara K, Oh DY, Kang YK, Chung HC, Kudo T, Chin K, Kadowaki S, Hamamoto Y, Hironaka S, Yoshida K, Yen CJ, Omuro Y, Bai LY, Maeda K, Ozeki A, Yoshikawa R, Kitagawa Y. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial. JAMA Netw Open. 2019 Aug 2;2(8):e198243. doi: 10.1001/jamanetworkopen.2019.8243. PubMed 31373648 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Oct 2017, 24 months.

Results were first posted in Feb 2019, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2015
First posted
Sep 2, 2015
StartActual
Oct 5, 2015
Primary completionActual
Oct 25, 2017
CompletionActual
Mar 10, 2021
Results first posted
Feb 15, 2019
Last update
Mar 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02539225
Responsible party
Sponsor
First posted
Sep 2, 2015
Start date
Oct 5, 2015
Primary completion
Oct 25, 2017
Completion
Mar 10, 2021
Results posted
Feb 15, 2019
Last update
Mar 8, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ramucirumab · Oxaliplatin · Paclitaxel

Start the discussion